Characterization	O
of	O
the	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
enhancer-binding	I-protein
proteins	I-protein
from	O
the	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
Jurkat	B-cell_line
.	O

The	O
transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
under	O
the	O
control	O
of	O
cellular	B-protein
proteins	I-protein
that	O
bind	O
to	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O

Among	O
the	O
protein-binding	O
regions	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
is	O
the	O
transcription-enhancer	B-DNA
region	I-DNA
.	O

We	O
show	O
that	O
at	O
least	O
one	O
inducible	B-protein
,	O
C1	B-protein
,	O
and	O
one	O
constitutive	B-protein
,	I-protein
C2	I-protein
,	I-protein
protein	I-protein
can	O
bind	O
to	O
the	O
HIV	B-DNA
enhancer	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

The	O
two	O
proteins	O
differ	O
in	O
their	O
surface	O
charge	O
,	O
since	O
they	O
are	O
separable	O
by	O
anion-exchange	O
chromatography	O
.	O

Bivalent	O
cations	O
such	O
as	O
Mg2+	O
and	O
Zn2+	O
differentially	O
affect	O
their	O
binding	O
to	O
oligonucleotides	O
which	O
contain	O
the	O
HIV-enhancer	B-DNA
domain	I-DNA
.	O

Both	O
C1	B-protein
and	O
C2	B-protein
proteins	I-protein
also	O
bind	O
to	O
a	O
similar	O
sequence	O
found	O
in	O
the	O
interleukin-2-receptor	B-DNA
alpha-subunit	I-DNA
enhancer	I-DNA
.	O

The	O
inducible	B-protein
C1	I-protein
protein	I-protein
was	O
partially	O
purified	O
by	O
three	O
chromatographic	O
steps	O
and	O
characterized	O
by	O
u.v.	O
cross-linking	O
as	O
a	O
47	B-protein
kDa	I-protein
protein	I-protein
.	O

Biochem	NULL
.	NULL

J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
265	NULL
,	NULL
547-554	NULL
(	NULL
Printed	NULL
in	NULL
Great	NULL
Britain	NULL
)	NULL
547	NULL
Characterization	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
enhancer-binding	NULL
proteins	NULL
from	NULL
the	NULL
human	NULL
T-cell	NULL
line	NULL
Jurkat	NULL
Marie	NULL
KORNER	NULL
,	NULL
*	NULL
Annick	NULL
Harel	NULL
BELLAN	NULL
,	NULL
f	NULL
Anna	NULL
T.	NULL
BRINI¢t	NULL
and	NULL
William	NULL
L.	NULL
FARRARt	NULL
*BCDP	NULL
,	NULL
Program	NULL
Resources	NULL
,	NULL
Inc.	NULL
,	NULL
NCl-Frederick	NULL
Cancer	NULL
Research	NULL
Facility	NULL
,	NULL
and	NULL
{	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Immunoregulation	NULL
,	NULL
Biological	NULL
Response	NULL
Modifiers	NULL
Program	NULL
,	NULL
Division	NULL
of	NULL
Cancer	NULL
Treatment	NULL
,	NULL
Frederick	NULL
Cancer	NULL
Research	NULL
Facility	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
21701-1013	NULL
,	NULL
U.S.A	NULL
.	NULL

The	NULL
transcription	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
is	NULL
under	NULL
the	NULL
control	NULL
of	NULL
cellular	NULL
proteins	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
viral	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
.	NULL

Among	NULL
the	NULL
protein-binding	NULL
regions	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
is	NULL
the	NULL
transcription-enhancer	NULL
region	NULL
.	NULL

We	NULL
show	NULL
that	NULL
at	NULL
least	NULL
one	NULL
inducible	NULL
,	NULL
C1	NULL
,	NULL
and	NULL
one	NULL
constitutive	NULL
,	NULL
C2	NULL
,	NULL
protein	NULL
can	NULL
bind	NULL
to	NULL
the	NULL
HIV	NULL
enhancer	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

The	NULL
two	NULL
proteins	NULL
differ	NULL
in	NULL
their	NULL
surface	NULL
charge	NULL
,	NULL
since	NULL
they	NULL
are	NULL
separable	NULL
by	NULL
anion-exchange	NULL
chromatography	NULL
.	NULL

Bivalent	NULL
cations	NULL
such	NULL
as	NULL
Mg**	NULL
and	NULL
Zn	NULL
>	NULL
*	NULL
differentially	NULL
affect	NULL
their	NULL
binding	NULL
to	NULL
oligonucleotides	NULL
which	NULL
contain	NULL
the	NULL
HIV-enhancer	NULL
domain	NULL
.	NULL

Both	NULL
C1	NULL
and	NULL
C2	NULL
proteins	NULL
also	NULL
bind	NULL
to	NULL
a	NULL
similar	NULL
sequence	NULL
found	NULL
in	NULL
the	NULL
interleukin-2-receptor	NULL
«	NULL
-subunit	NULL
enhancer	NULL
.	NULL

The	NULL
inducible	NULL
C1	NULL
protein	NULL
was	NULL
partially	NULL
purified	NULL
by	NULL
three	NULL
chromatographic	NULL
steps	NULL
and	NULL
characterized	NULL
by	NULL
u.v	NULL
.	NULL

cross-linking	NULL
as	NULL
a	NULL
47	NULL
kDa	NULL
protein	NULL
.	NULL

INTRODUCTION	NULL
Human	NULL
immunodeficiency	NULL
virus	NULL
1	NULL
(	NULL
HIV-	NULL
!	NULL
)	NULL

is	NULL
the	NULL
etiological	NULL
agent	NULL
of	NULL
AIDS	NULL
(	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
)	NULL
[	NULL
1,2	NULL
]	NULL
.	NULL

The	NULL
virus	NULL
typically	NULL
infects	NULL
cells	NULL
expressing	NULL
the	NULL
CD4	NULL
receptor	NULL
[	NULL
3,4	NULL
]	NULL
.	NULL

However	NULL
,	NULL
the	NULL
virus	NULL
is	NULL
able	NULL
to	NULL
express	NULL
its	NULL
gene	NULL
products	NULL
even	NULL
when	NULL
transfected	NULL
into	NULL
cells	NULL
that	NULL
do	NULL
not	NULL
express	NULL
the	NULL
CD4	NULL
receptor	NULL
,	NULL
such	NULL
as	NULL
HeLa	NULL
cells	NULL
[	NULL
5	NULL
]	NULL
.	NULL

These	NULL
observations	NULL
imply	NULL
that	NULL
HIV	NULL
is	NULL
able	NULL
to	NULL
use	NULL
host-cell	NULL
transcriptional	NULL
factors	NULL
common	NULL
to	NULL
many	NULL
cell	NULL
types	NULL
for	NULL
its	NULL
transcriptional	NULL
regulation	NULL
.	NULL

Deletion	NULL
analysis	NULL
of	NULL
chloramphenicol	NULL
acetyltransferase	NULL
constructs	NULL
(	NULL
CAT	NULL
assays	NULL
)	NULL
and	NULL
DN	NULL
Aase	NULL
footprinting	NULL
assays	NULL
of	NULL
the	NULL
HIV	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
have	NULL
revealed	NULL
that	NULL
at	NULL
least	NULL
five	NULL
distinct	NULL
regions	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
transcription	NULL
of	NULL
the	NULL
viral	NULL
genes	NULL
by	NULL
interacting	NULL
with	NULL
cellular	NULL
proteins	NULL
[	NULL
6	NULL
]	NULL
.	NULL

Among	NULL
these	NULL
regions	NULL
,	NULL
a	NULL
negative	NULL
regulatory	NULL
element	NULL
(	NULL
-	NULL
173	NULL
to	NULL
-159	NULL
)	NULL
and	NULL
a	NULL
positive	NULL
regulatory	NULL
element	NULL
or	NULL
enhancer	NULL
(	NULL
-	NULL
104	NULL
to	NULL
-78	NULL
)	NULL
have	NULL
been	NULL
identified	NULL
[	NULL
6-8	NULL
]	NULL
.	NULL

The	NULL
enhancer	NULL
element	NULL
is	NULL
composed	NULL
of	NULL
two	NULL
direct	NULL
repeats	NULL
of	NULL
the	NULL
sequence	NULL
GGGACTTTCC	NULL
[	NULL
8,9	NULL
]	NULL
.	NULL

This	NULL
sequence	NULL
is	NULL
identical	NULL
with	NULL
the	NULL
«	NULL
-light-chain-enhancer	NULL
sequence	NULL
or	NULL
«	NULL
B	NULL
site	NULL
,	NULL
except	NULL
that	NULL
the	NULL
sequence	NULL
is	NULL
not	NULL
repeated	NULL
[	NULL
10	NULL
]	NULL
.	NULL

The	NULL
«	NULL
-light-chain-enhancer	NULL
site	NULL
is	NULL
bound	NULL
by	NULL
a	NULL
constitutively	NULL
expressed	NULL
protein	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
in	NULL
mature	NULL
B-cells	NULL
.	NULL

In	NULL
pre-B-cells	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
induced	NULL
by	NULL
lipopolysaccharide	NULL
[	NULL
10	NULL
]	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
was	NULL
recently	NULL
purified	NULL
from	NULL
bovine	NULL
spleen	NULL
and	NULL
shown	NULL
to	NULL
be	NULL
a	NULL
42-44	NULL
kDa	NULL
protein	NULL
[	NULL
11	NULL
]	NULL
.	NULL

Furthermore	NULL
,	NULL
Nabel	NULL
&	NULL
Baltimore	NULL
[	NULL
9	NULL
]	NULL
showed	NULL
that	NULL
phorbol	NULL
ester	NULL
plus	NULL
mitogen	NULL
induced	NULL
a	NULL
protein	NULL
that	NULL
is	NULL
specific	NULL
to	NULL
a	NULL
human	NULL
T-cell	NULL
line	NULL
(	NULL
Jurkat	NULL
)	NULL
and	NULL
binds	NULL
to	NULL
the	NULL
HIV	NULL
enhancer	NULL
element	NULL
.	NULL

In	NULL
their	NULL
original	NULL
report	NULL
those	NULL
authors	NULL
postulated	NULL
that	NULL
the	NULL
HIV-enhancer-specific	NULL
binding	NULL
protein	NULL
in	NULL
Jurkat	NULL
cells	NULL
is	NULL
identical	NULL
with	NULL
B-cell	NULL
NF-	NULL
«	NULL
kB	NULL
.	NULL

Stimulation	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
lectin	NULL
and	NULL
phorbol	NULL
esters	NULL
induces	NULL
the	NULL
expression	NULL
of	NULL
both	NULL
interleukin-2	NULL
(	NULL
IL2	NULL
)	NULL
and	NULL
its	NULL
receptor	NULL
a-subunit	NULL
(	NULL
IL2Ra	NULL
)	NULL
.	NULL

Purified	NULL
NF-	NULL
«	NULL
B	NULL
binds	NULL
to	NULL
both	NULL
IL2	NULL
and	NULL
IL2Ra	NULL
enhancer	NULL
domains	NULL
[	NULL
11	NULL
]	NULL
.	NULL

However	NULL
,	NULL
another	NULL
protein	NULL
,	NULL
HIVEN	NULL
86A	NULL
,	NULL
characterized	NULL
in	NULL
the	NULL
same	NULL
cells	NULL
,	NULL
was	NULL
able	NULL
to	NULL
bind	NULL
both	NULL
the	NULL
HIV	NULL
enhancer	NULL
element	NULL
[	NULL
12	NULL
]	NULL
and	NULL
the	NULL
IL2Ra	NULL
enhancer	NULL
[	NULL
13	NULL
]	NULL
.	NULL

Two	NULL
other	NULL
groups	NULL
have	NULL
purified	NULL
HIV	NULL
enhancer-binding	NULL
proteins	NULL
from	NULL
phorbol-ester-treated	NULL
HeLa	NULL
cells	NULL
[	NULL
14	NULL
]	NULL
and	NULL
the	NULL
Namalwa	NULL
B-cell	NULL
line	NULL
[	NULL
15	NULL
]	NULL
.	NULL

The	NULL
protein	NULL
purified	NULL
from	NULL
HeLa-cell	NULL
extracts	NULL
had	NULL
an	NULL
apparent	NULL
M	NULL
,	NULL
of	NULL
55000-60000	NULL
,	NULL
whereas	NULL
the	NULL
M	NULL
,	NULL
of	NULL
the	NULL
protein	NULL
from	NULL
the	NULL
Namalwa	NULL
cells	NULL
was	NULL
reported	NULL
to	NULL
be	NULL
51000	NULL
.	NULL

Therefore	NULL
both	NULL
lymphoid	NULL
and	NULL
non-lymphoid	NULL
cells	NULL
express	NULL
proteins	NULL
capable	NULL
of	NULL
specifically	NULL
binding	NULL
to	NULL
the	NULL
HIV	NULL
enhancer	NULL
domain	NULL
,	NULL
but	NULL
only	NULL
mature	NULL
B-cells	NULL
express	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
protein	NULL
constitutively	NULL
.	NULL

The	NULL
relationship	NULL
between	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
other	NULL
HIV	NULL
enhancer-binding	NULL
proteins	NULL
is	NULL
not	NULL
yet	NULL
elucidated	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
stimulation	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
phorbol	NULL
-	NULL
12-myristate	NULL
-	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
_	NULL
and	NULL
phytohaemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
induces	NULL
at	NULL
least	NULL
two	NULL
proteins	NULL
capable	NULL
of	NULL
binding	NULL
specifically	NULL
to	NULL
the	NULL
HIV	NULL
enhancer	NULL
element	NULL
.	NULL

We	NULL
describe	NULL
the	NULL
separation	NULL
of	NULL
these	NULL
proteins	NULL
and	NULL
the	NULL
partial	NULL
purification	NULL
and	NULL
characterization	NULL
of	NULL
the	NULL
major	NULL
47	NULL
kDa	NULL
protein	NULL
.	NULL

EXPERIMENTAL	NULL
Cell	NULL
culture	NULL
The	NULL
Jurkat	NULL
T-cell	NULL
line	NULL
was	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
fetal-calf	NULL
serum	NULL
,	NULL
glutamine	NULL
and	NULL
penicillin/streptomycin	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
3h	NULL
with	NULL
21g	NULL
of	NULL
PHA	NULL
(	NULL
Burroughs	NULL
Wellcome	NULL
)	NULL
and	NULL
50	NULL
ng	NULL
of	NULL
PMA	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

Protein	NULL
extraction	NULL
Whole	NULL
cell	NULL
extracts	NULL
were	NULL
obtained	NULL
as	NULL
described	NULL
previously	NULL
[	NULL
16	NULL
]	NULL
.	NULL

The	NULL
final	NULL
protein	NULL
extract	NULL
contained	NULL
5-25	NULL
mg	NULL
Abbreviations	NULL
used	NULL
:	NULL
LTR	NULL
,	NULL
long	NULL
terminal	NULL
repeat	NULL
;	NULL
HIV	NULL
(	NULL
-1	NULL
)	NULL
,	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
;	NULL
AIDS	NULL
,	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
;	NULL
IL2	NULL
,	NULL
interleukin	NULL
2	NULL
;	NULL
IL2Ra	NULL
,	NULL
IL2-receptor	NULL
a-subunit	NULL
;	NULL
PMSF	NULL
,	NULL
phenylmethanesulphonyl	NULL
fluoride	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
1l3-acetate	NULL
;	NULL
PHA	NULL
,	NULL
phytohaemagglutinin	NULL
;	NULL
CRE	NULL
,	NULL
cyclic	NULL
AMP-responsive	NULL
element	NULL
;	NULL
Brd	NULL
UTP	NULL
,	NULL
5-bromo-2'-deoxyuridine	NULL
5'-triphosphate	NULL
;	NULL
DTT	NULL
,	NULL
dithiothreitol	NULL
.	NULL

Vol	NULL
.	NULL

265	NULL
548	NULL
of	NULL
protein/ml	NULL
of	NULL
buffer	NULL
A50	NULL
[	NULL
50	NULL
mm-	NULL
(	NULL
NH	NULL
,	NULL
)	NULL
,	NULL
SO	NULL
,	NULL
/1	NULL
mm-EDTA/10	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
glycerol/1	NULL
mm-dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
/	NULL
20	NULL
mm-Tris/HCl	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
/1	NULL
mm-PMSF	NULL
]	NULL
.	NULL

The	NULL
extraction	NULL
procedure	NULL
included	NULL
an	NULL
(	NULL
NH	NULL
,	NULL
)	NULL
,	NULL
SO	NULL
,	NULL
precipitation	NULL
at	NULL
50	NULL
%	NULL
saturation	NULL
.	NULL

Cell	NULL
extracts	NULL
were	NULL
stored	NULL
at	NULL
-80	NULL
°C	NULL
.	NULL

Oligonucleotides	NULL
and	NULL
gel-retardation	NULL
assay	NULL
Two	NULL
synthetic	NULL
double-stranded	NULL
oligonucleotides	NULL
were	NULL
used	NULL
as	NULL
probes	NULL
for	NULL
detection	NULL
of	NULL
the	NULL
HIV	NULL
enhancer-binding	NULL
proteins	NULL
.	NULL

A	NULL
31-mer	NULL
oligonucleotide	NULL
or	NULL
'	NULL
Tandem	NULL
'	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
two	NULL
direct	NULL
repeats	NULL
of	NULL
the	NULL
HIV	NULL
enhancer	NULL
sequence	NULL
from	NULL
the	NULL
position	NULL
-107	NULL
to	NULL
-80	NULL
[	NULL
6	NULL
]	NULL
(	NULL
5'-ACAAGGGACTTTCCGCTGGGGACTTTCCAGG-	NULL
and	NULL
a	NULL
16-mer	NULL
oligonucleotide	NULL
or	NULL
'Mono	NULL
'	NULL
,	NULL
containing	NULL
only	NULL
the	NULL
5¢	NULL
site	NULL
from	NULL
the	NULL
position	NULL
-107	NULL
to	NULL
-92	NULL
.	NULL

Two	NULL
other	NULL
double-stranded	NULL
oligonucleotides	NULL
were	NULL
also	NULL
synthesized	NULL
:	NULL
a	NULL
16-mer	NULL
containing	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
IL2Ra	NULL
promoter	NULL
from	NULL
the	NULL
position	NULL
-270	NULL
to	NULL
-255	NULL
[	NULL
17	NULL
]	NULL
(	NULL
5-GCAGGGAATCTCCCT-3	NULL
'	NULL
)	NULL
and	NULL
_	NULL
a	NULL
-	NULL
33-mer	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
cyclic	NULL
AMP-responsive	NULL
element	NULL
(	NULL
CRE	NULL
)	NULL
of	NULL
the	NULL
human	NULL
pro-enkephalin	NULL
from	NULL
the	NULL
position	NULL
-108	NULL
to	NULL
-76	NULL
[	NULL
18	NULL
]	NULL
(	NULL
5-GGGCTGGCGTAGG-GCCTGCGTCAGCTGCAGCCC-3	NULL
'	NULL
)	NULL
.	NULL

In	NULL
the	NULL
u.v	NULL
.	NULL

cross-linking	NULL
experiments	NULL
,	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
APIl/c-Jun	NULL
binding	NULL
site	NULL
[	NULL
19	NULL
]	NULL
was	NULL
also	NULL
used	NULL
(	NULL
5'-GATCCGGCTGACTCATG-3	NULL
'	NULL
)	NULL
.	NULL

The	NULL
oligonucleotide	NULL
probes	NULL
were	NULL
end-labelled	NULL
with	NULL
phage-T	NULL
,	NULL
kinase	NULL
.	NULL

The	NULL
gel-retardation	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
follows	NULL
:	NULL
5	NULL
ul	NULL
of	NULL
protein	NULL
solution	NULL
(	NULL
0.4-200	NULL
ug	NULL
)	NULL
was	NULL
incubated	NULL
on	NULL
ice	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
20	NULL
ul	NULL
of	NULL
20	NULL
mm-Tris/HCl	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
/10	NULL
%	NULL
glycerol	NULL
/	NULL
1	NULL
mm-DTT	NULL
/	NULL
60	NULL
mm-KCI	NULL
/	NULL
poly-	NULL
(	NULL
dI	NULL
-dC	NULL
)	NULL
(	NULL
2	NULL
ug	NULL
)	NULL
.	NULL

After	NULL
15	NULL
min	NULL
incubation	NULL
,	NULL
the	NULL
*	NULL
%	NULL
P-end-labelled	NULL
oligonucleotide	NULL
was	NULL
added	NULL
(	NULL
100000-500000	NULL
c.p.m	NULL
.	NULL

;	NULL
0.1	NULL
ng	NULL
)	NULL
and	NULL
the	NULL
binding	NULL
reaction	NULL
was	NULL
allowed	NULL
to	NULL
proceed	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
15	NULL
min	NULL
.	NULL

The	NULL
bound	NULL
oligonucleotide	NULL
was	NULL
separated	NULL
from	NULL
the	NULL
free	NULL
by	NULL
electrophoresis	NULL
on	NULL
a	NULL
6	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
0.25X	NULL
TBE	NULL
[	NULL
22.5	NULL
mm-Tris/borate	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
/0.5	NULL
mm-EDTA	NULL
]	NULL
.	NULL

The	NULL
specific	NULL
activity	NULL
was	NULL
determined	NULL
as	NULL
described	NULL
by	NULL
Yano	NULL
et	NULL
al	NULL
.	NULL

[	NULL
20	NULL
]	NULL
,	NULL
except	NULL
that	NULL
the	NULL
radioactivity	NULL
of	NULL
the	NULL
bands	NULL
was	NULL
counted	NULL
by	NULL
the	NULL
Cerenkov	NULL
rather	NULL
than	NULL
the	NULL
liquid-scintillation	NULL
method	NULL
,	NULL
and	NULL
the	NULL
control	NULL
DNA	NULL
was	NULL
the	NULL
unbound	NULL
free	NULL
oligonucleotide	NULL
.	NULL

The	NULL
specific	NULL
activity	NULL
is	NULL
expressed	NULL
as	NULL
pg	NULL
of	NULL
retarded	NULL
radiolabelled	NULL
probe/mg	NULL
of	NULL
protein	NULL
.	NULL

Total	NULL
activity	NULL
was	NULL
obtained	NULL
by	NULL
multiplying	NULL
the	NULL
specific	NULL
activity	NULL
by	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
protein	NULL
and	NULL
is	NULL
therefore	NULL
also	NULL
expressed	NULL
in	NULL
pg	NULL
.	NULL

H.p.l.c	NULL
.	NULL

and	NULL
affinity-chromatographic	NULL
fractionation	NULL
The	NULL
whole-cell	NULL
extract	NULL
from	NULL
25	NULL
x	NULL
10°	NULL
cells	NULL
(	NULL
400	NULL
mg	NULL
of	NULL
protein	NULL
)	NULL
was	NULL
diluted	NULL
3-fold	NULL
with	NULL
the	NULL
column	NULL
buffer	NULL
[	NULL
20	NULL
mm-Tris/HCl	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
/1	NULL
mm-EDTA	NULL
)	NULL
and	NULL
loaded	NULL
on	NULL
to	NULL
a	NULL
Bio-Gel	NULL
TSK-DEAE-5-PW	NULL
column	NULL
at	NULL
a	NULL
flow	NULL
rate	NULL
of	NULL
5	NULL
ml/min	NULL
.	NULL

The	NULL
column	NULL
was	NULL
washed	NULL
with	NULL
twice	NULL
its	NULL
volume	NULL
of	NULL
column	NULL
buffer	NULL
,	NULL
and	NULL
the	NULL
bound	NULL
proteins	NULL
were	NULL
eluted	NULL
with	NULL
a	NULL
linear	NULL
gradient	NULL
of	NULL
KCI	NULL
(	NULL
0O-0.5	NULL
m	NULL
)	NULL
.	NULL

The	NULL
5	NULL
ml	NULL
fractions	NULL
were	NULL
dialysed	NULL
against	NULL
the	NULL
A50	NULL
buffer	NULL
and	NULL
tested	NULL
for	NULL
their	NULL
HIV	NULL
enhancer-binding	NULL
activity	NULL
by	NULL
the	NULL
DNA	NULL
gel-retardation	NULL
assay	NULL
.	NULL

The	NULL
fractions	NULL
containing	NULL
the	NULL
PMA	NULL
+	NULL
PHA-induced	NULL
proteins	NULL
were	NULL
pooled	NULL
(	NULL
pool	NULL
1	NULL
;	NULL
see	NULL
Fig	NULL
.	NULL

3	NULL
below	NULL
)	NULL
and	NULL
further	NULL
fractionated	NULL
by	NULL
affinity	NULL
chromatography	NULL
by	NULL
using	NULL
a	NULL
trimeric	NULL
repeat	NULL
of	NULL
the	NULL
mono	NULL
oligonucleotide	NULL
(	NULL
a	NULL
48-mer	NULL
)	NULL
covalently	NULL
bound	NULL
to	NULL
a	NULL
CNBr-activated	NULL
Sepharose	NULL
(	NULL
Pharmacia	NULL
)	NULL
as	NULL
described	NULL
in	NULL
[	NULL
21	NULL
]	NULL
.	NULL

The	NULL
density	NULL
of	NULL
the	NULL
oligonucleotide	NULL
was	NULL
approx	NULL
.	NULL

140	NULL
ug/g	NULL
of	NULL
dry	NULL
gel	NULL
.	NULL

The	NULL
proteins	NULL
were	NULL
loaded	NULL
at	NULL
a	NULL
rate	NULL
of	NULL
0.5	NULL
ml/min	NULL
.	NULL

The	NULL
M.	NULL
Korner	NULL
and	NULL
others	NULL
unbound	NULL
material	NULL
was	NULL
washed	NULL
out	NULL
with	NULL
2.5	NULL
column	NULL
volumes	NULL
of	NULL
the	NULL
A50	NULL
buffer	NULL
.	NULL

The	NULL
bound	NULL
proteins	NULL
were	NULL
eluted	NULL
in	NULL
2	NULL
ml	NULL
fractions	NULL
by	NULL
a	NULL
discontinuous	NULL
gradient	NULL
of	NULL
KCl	NULL
(	NULL
0.2	NULL
,	NULL
0.5	NULL
and	NULL
1.0	NULL
M	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
0.05	NULL
%	NULL
Nonidet	NULL
P40	NULL
.	NULL

After	NULL
dialysing	NULL
the	NULL
fractions	NULL
against	NULL
the	NULL
A50	NULL
buffer	NULL
,	NULL
the	NULL
DNA-binding	NULL
activity	NULL
was	NULL
assayed	NULL
by	NULL
the	NULL
DNA	NULL
gel-retardation	NULL
assay	NULL
.	NULL

The	NULL
active	NULL
dialysed	NULL
fractions	NULL
were	NULL
pooled	NULL
,	NULL
and	NULL
the	NULL
affinity	NULL
chromatography	NULL
was	NULL
repeated	NULL
a	NULL
second	NULL
time	NULL
.	NULL

U.v	NULL
.	NULL

cross-linking	NULL
The	NULL
probe	NULL
used	NULL
for	NULL
the	NULL
u.v	NULL
.	NULL

cross-linking	NULL
experiment	NULL
was	NULL
prepared	NULL
by	NULL
following	NULL
the	NULL
instructions	NULL
of	NULL
the	NULL
manufacturer	NULL
(	NULL
Boehringer-Mannheim	NULL
)	NULL
;	NULL
the	NULL
Tandem	NULL
single-stranded	NULL
oligonucleotide	NULL
was	NULL
added	NULL
to	NULL
the	NULL
Bochringer-Mannheim	NULL
random	NULL
primed	NULL
DNA	NULL
labelling	NULL
kit	NULL
mixture	NULL
.	NULL

A	NULL
100	NULL
4Ci	NULL
portion	NULL
of	NULL
[	NULL
P	NULL
]	NULL
dCTP	NULL
and	NULL
0.5	NULL
nmol	NULL
of	NULL
BrdUTP	NULL
were	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixture	NULL
.	NULL

After	NULL
30	NULL
min	NULL
incubation	NULL
at	NULL
37	NULL
°C	NULL
,	NULL
0.5	NULL
nmol	NULL
of	NULL
dCTP	NULL
were	NULL
added	NULL
.	NULL

The	NULL
labelled	NULL
probe	NULL
was	NULL
purified	NULL
from	NULL
the	NULL
free	NULL
nucleotides	NULL
by	NULL
two	NULL
passages	NULL
through	NULL
Sepharose	NULL
G-25	NULL
.	NULL

Its	NULL
radioactivity	NULL
averaged	NULL
500000	NULL
c.p.m./wl	NULL
.	NULL

The	NULL
u.v	NULL
.	NULL

cross-linking	NULL
of	NULL
proteins	NULL
with	NULL
the	NULL
*°P-labelled	NULL
BrdUr-substituted	NULL
Tandem	NULL
oligonucleotide	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
[	NULL
22	NULL
]	NULL
,	NULL
except	NULL
that	NULL
after	NULL
irradiation	NULL
the	NULL
samples	NULL
were	NULL
immediately	NULL
boiled	NULL
in	NULL
2.5	NULL
%	NULL
SDS/1	NULL
mm-EDTA/20	NULL
%	NULL
glycerol/1	NULL
%	NULL
2-mercaptoethanol	NULL
.	NULL

The	NULL
electrophoretic	NULL
separation	NULL
was	NULL
performed	NULL
on	NULL
10	NULL
%	NULL
-polyacrylamide	NULL
gels	NULL
as	NULL
described	NULL
by	NULL
Porzio	NULL
&	NULL
Pearson	NULL
[	NULL
23	NULL
]	NULL
.	NULL

RESULTS	NULL
Induction	NULL
of	NULL
HIV	NULL
enhancer-binding	NULL
proteins	NULL
We	NULL
first	NULL
examined	NULL
the	NULL
capacity	NULL
of	NULL
proteins	NULL
extracted	NULL
from	NULL
Jurkat	NULL
cells	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
synthetic	NULL
oligonucleotides	NULL
which	NULL
represented	NULL
either	NULL
a	NULL
single	NULL
copy	NULL
(	NULL
Mono	NULL
)	NULL
or	NULL
two	NULL
copies	NULL
(	NULL
Tandem	NULL
)	NULL
of	NULL
the	NULL
«	NULL
B	NULL
site	NULL
of	NULL
the	NULL
HIV	NULL
enhancer	NULL
domain	NULL
.	NULL

Both	NULL
oligonucleotides	NULL
formed	NULL
two	NULL
protein-DNA	NULL
complexes	NULL
,	NULL
C1	NULL
and	NULL
C2	NULL
,	NULL
with	NULL
distinct	NULL
electrophoretic	NULL
mobilities	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
C1	NULL
complex	NULL
was	NULL
greatly	NULL
increased	NULL
by	NULL
the	NULL
stimulation	NULL
of	NULL
Jurkat	NULL
cells	NULL
by	NULL
PMA	NULL
and	NULL
PHA	NULL
.	NULL

This	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
previously	NULL
described	NULL
induction	NULL
of	NULL
HIV	NULL
enhancer-binding	NULL
proteins	NULL
in	NULL
Jurkat	NULL
cells	NULL
by	NULL
Nabel	NULL
&	NULL
Baltimore	NULL
[	NULL
9	NULL
]	NULL
.	NULL

In	NULL
their	NULL
study	NULL
the	NULL
radiolabelled	NULL
probe	NULL
used	NULL
was	NULL
much	NULL
larger	NULL
(	NULL
90	NULL
bp	NULL
)	NULL
compared	NULL
with	NULL
the	NULL
Tandem	NULL
oligonucleotide	NULL
and	NULL
included	NULL
an	NULL
upstream	NULL
50	NULL
bp	NULL
extension	NULL
.	NULL

The	NULL
single	NULL
«	NULL
B	NULL
site	NULL
(	NULL
Mono	NULL
)	NULL
-retarded	NULL
migration	NULL
was	NULL
undistinguishable	NULL
from	NULL
that	NULL
of	NULL
the	NULL
Tandem	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
two	NULL
oligonucleotides	NULL
bind	NULL
the	NULL
same	NULL
proteins	NULL
.	NULL

It	NULL
is	NULL
also	NULL
very	NULL
likely	NULL
that	NULL
the	NULL
two	NULL
potential	NULL
«	NULL
B	NULL
sites	NULL
in	NULL
the	NULL
Tandem	NULL
oligonucleotide	NULL
can	NULL
not	NULL
bind	NULL
proteins	NULL
simultaneously	NULL
,	NULL
since	NULL
no	NULL
slower	NULL
migrating	NULL
complex	NULL
than	NULL
that	NULL
of	NULL
C1	NULL
was	NULL
seen	NULL
with	NULL
the	NULL
Tandem	NULL
.	NULL

However	NULL
the	NULL
length	NULL
of	NULL
the	NULL
probe	NULL
is	NULL
critical	NULL
,	NULL
since	NULL
we	NULL
did	NULL
not	NULL
see	NULL
any	NULL
retardation	NULL
of	NULL
Mono	NULL
oligonucleotides	NULL
shorter	NULL
than	NULL
14	NULL
bp	NULL
.	NULL

This	NULL
observation	NULL
may	NULL
be	NULL
attributable	NULL
to	NULL
the	NULL
high	NULL
dissociation	NULL
rate	NULL
of	NULL
the	NULL
protein-DNA	NULL
complex	NULL
with	NULL
short	NULL
DNA	NULL
probes	NULL
.	NULL

The	NULL
C1	NULL
complex	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
cycloheximide	NULL
and	NULL
actinomycin	NULL
D	NULL
treatment	NULL
of	NULL
Jurkat	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
its	NULL
induction	NULL
is	NULL
not	NULL
due	NULL
to	NULL
protein	NULL
synthesis	NULL
de	NULL
novo	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
C2-complex	NULL
in	NULL
contrast	NULL
with	NULL
the	NULL
Cl-complex	NULL
proteins	NULL
appear	NULL
to	NULL
be	NULL
constitutively	NULL
active	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Ionic	NULL
requirement	NULL
of	NULL
the	NULL
C1	NULL
and	NULL
C2	NULL
complexes	NULL
We	NULL
further	NULL
characterized	NULL
the	NULL
DNA	NULL
binding	NULL
of	NULL
C1	NULL
and	NULL
1990	NULL
Human	NULL
immunodeficiency	NULL
virus	NULL
enhancer-binding	NULL
proteins	NULL
Oligo	NULL
...	NULL
Mono	NULL
Tandem	NULL
PMA+	NULL
PHA	NULL
...	NULL
-	NULL
+	NULL
-	NULL
0+	NULL
&	NULL
+	NULL
«	NULL
a	NULL
goa	NULL
.	NULL

am	NULL
C2	NULL
-	NULL
»	NULL
Free	NULL
-	NULL
»	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Induction	NULL
of	NULL
HIV	NULL
enhancer-binding	NULL
proteins	NULL
in	NULL
Jurkat	NULL
cells	NULL
Gel	NULL
retardation	NULL
of	NULL
*P-labelled	NULL
Mono	NULL
and	NULL
Tandem	NULL
oligonucleotides	NULL
(	NULL
Oligo	NULL
)	NULL
by	NULL
proteins	NULL
(	NULL
15	NULL
ug	NULL
)	NULL
extracted	NULL
from	NULL
PMA	NULL
+	NULL
PHA-stimulated	NULL
(	NULL
+	NULL
)	NULL
or	NULL
unstimulated	NULL
(	NULL
-	NULL
)	NULL
Jurkat	NULL
cells	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
the	NULL
Experimental	NULL
section	NULL
.	NULL

Cl	NULL
and	NULL
C2	NULL
indicate	NULL
the	NULL
migration	NULL
of	NULL
the	NULL
oligonucleotides	NULL
complexed	NULL
to	NULL
the	NULL
proteins	NULL
.	NULL

'Free	NULL
'	NULL
refers	NULL
to	NULL
the	NULL
free	NULL
oligonucleotides	NULL
.	NULL

549	NULL
C2	NULL
by	NULL
studying	NULL
the	NULL
effect	NULL
of	NULL
ions	NULL
on	NULL
their	NULL
interaction	NULL
with	NULL
the	NULL
mono	NULL
probe	NULL
.	NULL

Bivalent	NULL
cations	NULL
such	NULL
as	NULL
Zn**	NULL
,	NULL
Ca**	NULL
and	NULL
Mg**	NULL
had	NULL
differential	NULL
effects	NULL
on	NULL
the	NULL
stability	NULL
of	NULL
C1	NULL
and	NULL
C2	NULL
complexes	NULL
.	NULL

At	NULL
1	NULL
mm	NULL
,	NULL
inhibited	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
C1	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
whereas	NULL
Mg**	NULL
and	NULL
Ca**	NULL
did	NULL
not	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
8	NULL
)	NULL
.	NULL

At	NULL
higher	NULL
Zn*	NULL
``	NULL
*	NULL
concentrations	NULL
(	NULL
2	NULL
and	NULL
5mm	NULL
)	NULL
Cl	NULL
complex	NULL
was	NULL
dissociated	NULL
,	NULL
whereas	NULL
the	NULL
C2	NULL
complex	NULL
was	NULL
greatly	NULL
augmented	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

At	NULL
the	NULL
same	NULL
concentrations	NULL
Ca®*	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
stability	NULL
of	NULL
either	NULL
C1	NULL
or	NULL
C2	NULL
,	NULL
whereas	NULL
Mg**	NULL
(	NULL
5	NULL
mm	NULL
)	NULL
had	NULL
a	NULL
dissociating	NULL
effect	NULL
on	NULL
the	NULL
C1	NULL
complex	NULL
without	NULL
affecting	NULL
the	NULL
C2	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

EDTA	NULL
(	NULL
10	NULL
mm	NULL
)	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
C1	NULL
complex	NULL
,	NULL
favoured	NULL
partial	NULL
dissociation	NULL
of	NULL
C2	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lane	NULL
11	NULL
)	NULL
and	NULL
efficiently	NULL
abolished	NULL
the	NULL
dissociating	NULL
effect	NULL
of	NULL
Mg**	NULL
on	NULL
the	NULL
C1	NULL
complex	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

C1	NULL
and	NULL
C2	NULL
also	NULL
differed	NULL
in	NULL
their	NULL
sensitivity	NULL
to	NULL
high	NULL
ionic	NULL
strength	NULL
,	NULL
since	NULL
C1	NULL
was	NULL
more	NULL
easily	NULL
dissociated	NULL
by	NULL
0.4	NULL
M-KC1	NULL
than	NULL
was	NULL
C2	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lane	NULL
12	NULL
)	NULL
.	NULL

Therefore	NULL
it	NULL
is	NULL
possible	NULL
to	NULL
favour	NULL
selectively	NULL
the	NULL
binding	NULL
of	NULL
either	NULL
Cl	NULL
or	NULL
C2	NULL
proteins	NULL
to	NULL
the	NULL
HIV	NULL
enhancer	NULL
by	NULL
manipulating	NULL
the	NULL
ionic	NULL
composition	NULL
of	NULL
the	NULL
reaction	NULL
medium	NULL
.	NULL

Isolation	NULL
of	NULL
the	NULL
Cl-complex	NULL
protein	NULL
In	NULL
order	NULL
to	NULL
isolate	NULL
the	NULL
inducible	NULL
C1-complex	NULL
proteins	NULL
we	NULL
performed	NULL
the	NULL
fractionation	NULL
and	NULL
oligonucleotide-binding	NULL
assays	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Mg**	NULL
ions	NULL
.	NULL

The	NULL
first	NULL
chromatographic	NULL
fractionation	NULL
was	NULL
performed	NULL
with	NULL
DEAE-S5PW	NULL
h.p.l.c	NULL
.	NULL

About	NULL
70	NULL
%	NULL
of	NULL
the	NULL
loaded	NULL
proteins	NULL
did	NULL
bind	NULL
to	NULL
the	NULL
column	NULL
(	NULL
Fig	NULL
.	NULL

3b	NULL
)	NULL
.	NULL

The	NULL
oligonucleotide-binding	NULL
activity	NULL
was	NULL
found	NULL
exclusively	NULL
in	NULL
the	NULL
KCl-eluted	NULL
fractions	NULL
,	NULL
suggesting	NULL
that	NULL
all	NULL
the	NULL
active	NULL
proteins	NULL
bound	NULL
to	NULL
the	NULL
DEAE	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
)	NULL
.	NULL

The	NULL
proteins	NULL
migrating	NULL
as	NULL
C2	NULL
``	NULL
were	NULL
Lane	NULL
...	NULL
1	NULL
2	NULL
3	NULL
4	NULL
C1	NULL
--	NULL
>	NULL
C2	NULL
-	NULL
>	NULL
Free	NULL
--	NULL
»	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Ion-dependence	NULL
of	NULL
oligonucleotide-protein	NULL
interaction	NULL
Gel	NULL
retardation	NULL
of	NULL
the	NULL
**P-labelled	NULL
mono	NULL
oligonucleotide	NULL
was	NULL
performed	NULL
with	NULL
15	NULL
ug	NULL
of	NULL
stimulated	NULL
Jurkat-cell	NULL
extracts	NULL
,	NULL
either	NULL
under	NULL
the	NULL
standard	NULL
conditions	NULL
described	NULL
in	NULL
the	NULL
Experimental	NULL
section	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
,	NULL
2	NULL
or	NULL
5	NULL
mm-ZnSO	NULL
,	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
3	NULL
and	NULL
4	NULL
)	NULL
;	NULL
1	NULL
,	NULL
2	NULL
or	NULL
5	NULL
mm-MgCl	NULL
,	NULL
(	NULL
lanes	NULL
5	NULL
,	NULL
6	NULL
and	NULL
7	NULL
)	NULL
;	NULL
1	NULL
,	NULL
2	NULL
or	NULL
5	NULL
mm-CaCl	NULL
,	NULL
(	NULL
lanes	NULL
8	NULL
,	NULL
9	NULL
and	NULL
10	NULL
)	NULL
;	NULL
10	NULL
mm-EDTA	NULL
(	NULL
lane	NULL
11	NULL
)	NULL
and	NULL
40	NULL
mm-KCl	NULL
(	NULL
lane	NULL
12	NULL
)	NULL
.	NULL

'Free	NULL
'	NULL
refers	NULL
to	NULL
the	NULL
free	NULL
oligonucleotides	NULL
.	NULL

*C1	NULL
'	NULL
and	NULL
°C2°	NULL
refer	NULL
to	NULL
the	NULL
complexes	NULL
.	NULL

Vol	NULL
.	NULL

265	NULL
550	NULL
(	NULL
a	NULL
)	NULL
Pool	NULL
2	NULL
M.	NULL
Korner	NULL
and	NULL
others	NULL
Pool	NULL
1	NULL
Pool	NULL
3	NULL
[	NULL
CCO	NULL
__	NULL
Cls	NULL
as	NULL
ald	NULL
any	NULL
l	NULL
Lane	NULL
...	NULL

I	NULL
13141516	NULL
17	NULL
1819	NULL
20	NULL
2122	NULL
23	NULL
24	NULL
25	NULL
26	NULL
27	NULL
28	NULL
29	NULL
30	NULL
31	NULL
32	NULL
33	NULL
3435	NULL
3637	NULL
38	NULL
FT	NULL
C1	NULL
©2	NULL
,	NULL
C2	NULL
--	NULL
>	NULL
tub	NULL
bub	NULL
but	NULL
i	NULL
#	NULL
@	NULL
w	NULL
son	NULL
wis	NULL
wha	NULL
#	NULL
s	NULL
a	NULL
m	NULL
A280	NULL
FT	NULL
-	NULL
W1_	NULL
W2	NULL
1	NULL
1	NULL
L	NULL
1	NULL
5	NULL
10	NULL
1520	NULL
25	NULL
30	NULL
35	NULL
40	NULL
45	NULL
50	NULL
55	NULL
60	NULL
1.0	NULL
[	NULL
KCH	NULL
(	NULL
m	NULL
)	NULL
KCI	NULL
gradient	NULL
1	NULL
1	NULL
L_	NULL
1	NULL
__|	NULL
1	NULL
1	NULL
Fraction	NULL
no	NULL
.	NULL

Fig	NULL
.	NULL

3	NULL
.	NULL

Fractionation	NULL
of	NULL
proteins	NULL
extracted	NULL
from	NULL
stimulated	NULL
Jurkat	NULL
cells	NULL
by	NULL
DEAE-cellulose	NULL
h.p.l.c	NULL
.	NULL

(	NULL
a	NULL
)	NULL
shows	NULL
the	NULL
gel	NULL
retardation	NULL
of	NULL
Mono	NULL
oligonucleotide	NULL
by	NULL
the	NULL
DEAE	NULL
h.p.l.c	NULL
.	NULL

fractions	NULL
.	NULL

The	NULL
migration	NULL
of	NULL
the	NULL
oligonucleotide	NULL
retarded	NULL
by	NULL
the	NULL
initial	NULL
extract	NULL
is	NULL
shown	NULL
in	NULL
lane	NULL
I.	NULL
C1	NULL
and	NULL
C2	NULL
indicate	NULL
the	NULL
migration	NULL
of	NULL
the	NULL
oligonucleotide	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
fractions	NULL
from	NULL
respectively	NULL
pools	NULL
1	NULL
and	NULL
3	NULL
,	NULL
whereas	NULL
C2	NULL
'	NULL
indicates	NULL
the	NULL
faster-migrating	NULL
complexes	NULL
from	NULL
pool	NULL
2	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Represents	NULL
the	NULL
recording	NULL
of	NULL
the	NULL
protein	NULL
elution	NULL
from	NULL
the	NULL
column	NULL
by	NULL
absorbance	NULL
at	NULL
280	NULL
nm	NULL
.	NULL

The	NULL
flow-through	NULL
(	NULL
FT	NULL
)	NULL
and	NULL
the	NULL
washings	NULL
(	NULL
W1	NULL
and	NULL
W2	NULL
)	NULL
were	NULL
collected	NULL
separately	NULL
.	NULL

eluted	NULL
with	NULL
0.15	NULL
m-KCI	NULL
and	NULL
pooled	NULL
(	NULL
pool	NULL
2	NULL
;	NULL
Fig	NULL
.	NULL

3a	NULL
)	NULL
.	NULL

The	NULL
C1	NULL
proteins	NULL
were	NULL
eluted	NULL
at	NULL
higher	NULL
salt	NULL
concentrations	NULL
(	NULL
0.22-0.25	NULL
m-KCI1	NULL
)	NULL
(	NULL
pool	NULL
1	NULL
)	NULL
.	NULL

A	NULL
third	NULL
pool	NULL
(	NULL
pool	NULL
3	NULL
,	NULL
fractions	NULL
30-33	NULL
)	NULL
,	NULL
contained	NULL
both	NULL
the	NULL
C1	NULL
and	NULL
C2	NULL
proteins	NULL
eluted	NULL
with	NULL
0.25-0.3	NULL
M-KCI	NULL
.	NULL

The	NULL
C2	NULL
and	NULL
C2	NULL
'	NULL
proteins	NULL
either	NULL
co-migrated	NULL
in	NULL
the	NULL
unfractionated	NULL
extract	NULL
or	NULL
one	NULL
of	NULL
the	NULL
two	NULL
activities	NULL
was	NULL
generated	NULL
by	NULL
the	NULL
fractionation	NULL
procedure	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
fractionation	NULL
could	NULL
possibly	NULL
have	NULL
eliminated	NULL
an	NULL
inhibitor	NULL
of	NULL
one	NULL
of	NULL
the	NULL
two	NULL
binding	NULL
activities	NULL
.	NULL

After	NULL
pooling	NULL
the	NULL
fractions	NULL
containing	NULL
the	NULL
same	NULL
binding	NULL
activities	NULL
,	NULL
we	NULL
analysed	NULL
the	NULL
specificity	NULL
of	NULL
their	NULL
binding	NULL
to	NULL
the	NULL
*°P-labelled	NULL
Mono	NULL
probe	NULL
by	NULL
competition	NULL
with	NULL
a	NULL
100-fold	NULL
excess	NULL
of	NULL
unlabelled	NULL
oligonucleotides	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

The	NULL
unlabelled	NULL
Mono	NULL
and	NULL
Tandem	NULL
oligonucleotides	NULL
competed	NULL
for	NULL
binding	NULL
to	NULL
Cl	NULL
and	NULL
C2	NULL
'	NULL
,	NULL
but	NULL
not	NULL
C2	NULL
.	NULL

The	NULL
IL2Ra	NULL
enhancer	NULL
probe	NULL
partially	NULL
inhibited	NULL
the	NULL
binding	NULL
of	NULL
C1	NULL
and	NULL
C2	NULL
'	NULL
and	NULL
not	NULL
C2	NULL
(	NULL
lanes	NULL
5	NULL
,	NULL
10	NULL
and	NULL
15	NULL
)	NULL
.	NULL

To	NULL
check	NULL
the	NULL
selectivity	NULL
of	NULL
binding	NULL
of	NULL
the	NULL
three	NULL
pools	NULL
to	NULL
the	NULL
«	NULL
B	NULL
site	NULL
,	NULL
we	NULL
used	NULL
the	NULL
CRE	NULL
oligonucleotide	NULL
as	NULL
a	NULL
competitor	NULL
,	NULL
since	NULL
it	NULL
contains	NULL
a	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
cyclic	NULL
AMP-induced	NULL
nuclear	NULL
proteins	NULL
.	NULL

The	NULL
CRE	NULL
oligonucleotide	NULL
has	NULL
no	NULL
sequence	NULL
similarity	NULL
with	NULL
the	NULL
«	NULL
B	NULL
site	NULL
(	NULL
see	NULL
the	NULL
Experimental	NULL
section	NULL
)	NULL
.	NULL

CRE	NULL
probes	NULL
did	NULL
not	NULL
compete	NULL
for	NULL
binding	NULL
Ci	NULL
and	NULL
C2	NULL
'	NULL
,	NULL
but	NULL
partially	NULL
inhibited	NULL
the	NULL
binding	NULL
of	NULL
C2	NULL
(	NULL
lanes	NULL
4	NULL
,	NULL
9	NULL
and	NULL
14	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
Cl	NULL
and	NULL
CZ	NULL
'	NULL
binding	NULL
activities	NULL
are	NULL
specific	NULL
for	NULL
binding	NULL
the	NULL
HIV	NULL
enhancer	NULL
probes	NULL
,	NULL
but	NULL
the	NULL
C2	NULL
protein	NULL
complex	NULL
is	NULL
not	NULL
.	NULL

The	NULL
IL2Ra	NULL
enhancer	NULL
probe	NULL
sequence	NULL
is	NULL
similar	NULL
to	NULL
,	NULL
but	NULL
not	NULL
identical	NULL
with	NULL
,	NULL
the	NULL
«	NULL
B	NULL
site	NULL
,	NULL
which	NULL
may	NULL
explain	NULL
why	NULL
it	NULL
appears	NULL
to	NULL
have	NULL
a	NULL
lower	NULL
affinity	NULL
for	NULL
C1	NULL
and	NULL
C2	NULL
'	NULL
binding	NULL
activities	NULL
(	NULL
see	NULL
also	NULL
Fig	NULL
.	NULL

6	NULL
below	NULL
)	NULL
.	NULL

The	NULL
sensitivity	NULL
to	NULL
Mg**	NULL
of	NULL
fractionated	NULL
C1	NULL
binding	NULL
activity	NULL
remained	NULL
unchanged	NULL
compared	NULL
with	NULL
the	NULL
C1	NULL
binding	NULL
activity	NULL
from	NULL
the	NULL
initial	NULL
extract	NULL
.	NULL

C2	NULL
'	NULL
complex	NULL
was	NULL
also	NULL
inhibited	NULL
by	NULL
5	NULL
mm-Mg**	NULL
,	NULL
whereas	NULL
C2	NULL
was	NULL
not	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
C2	NULL
binding	NULL
activity	NULL
in	NULL
the	NULL
initial	NULL
extract	NULL
was	NULL
mainly	NULL
due	NULL
to	NULL
proteins	NULL
from	NULL
pool	NULL
3	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
C1	NULL
binding	NULL
activity	NULL
from	NULL
pool	NULL
1	NULL
,	NULL
which	NULL
represents	NULL
1990	NULL
Human	NULL
immunodeficiency	NULL
virus	NULL
enhancer-binding	NULL
proteins	NULL
551	NULL
Pool	NULL
1	NULL
Pool	NULL
2	NULL
Pool	NULL
3	NULL
*	NULL
o	NULL
Zanes	NULL
Lane	NULL
..	NULL
100	NULL
2	NULL
3	NULL
40	NULL
5	NULL
7	NULL
s	NULL
9	NULL
10	NULL
11°	NULL
12	NULL
13	NULL
14	NULL
15	NULL
a	NULL
lab	NULL
``	NULL
lud	NULL
bd	NULL
I4	NULL
C2	NULL
,	NULL
C2	NULL
--	NULL
»	NULL
§	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Gel	NULL
retardation	NULL
of	NULL
**P-labelled	NULL
Mono	NULL
oligonucleotide	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
competitor	NULL
DNA	NULL
Lanes	NULL
1-5	NULL
show	NULL
the	NULL
result	NULL
of	NULL
the	NULL
assay	NULL
performed	NULL
with	NULL
fractions	NULL
from	NULL
the	NULL
pool	NULL
1	NULL
.	NULL

Lanes	NULL
6-10	NULL
and	NULL
13-15	NULL
represent	NULL
respectively	NULL
the	NULL
assay	NULL
with	NULL
pools	NULL
2	NULL
and	NULL
3	NULL
.	NULL

The	NULL
assay	NULL
performed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
competitor	NULL
DNA	NULL
is	NULL
shown	NULL
in	NULL
lanes	NULL
1	NULL
,	NULL
6	NULL
and	NULL
11	NULL
.	NULL

The	NULL
other	NULL
lanes	NULL
represent	NULL
the	NULL
retardation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100-fold	NULL
excess	NULL
of	NULL
Mono	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
7	NULL
and	NULL
12	NULL
)	NULL
,	NULL
Tandem	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
8	NULL
,	NULL
and	NULL
13	NULL
)	NULL
,	NULL
CRE	NULL
(	NULL
lanes	NULL
4	NULL
,	NULL
9	NULL
and	NULL
14	NULL
)	NULL
and	NULL
IL2Ra	NULL
enhancer	NULL
(	NULL
lanes	NULL
5	NULL
,	NULL
10	NULL
and	NULL
15	NULL
)	NULL
oligonucleotides	NULL
.	NULL

'Free	NULL
'	NULL
refers	NULL
to	NULL
the	NULL
free	NULL
oligonucleotide	NULL
.	NULL

the	NULL
major	NULL
induced	NULL
proteins	NULL
,	NULL
was	NULL
further	NULL
purified	NULL
by	NULL
two-step	NULL
affinity	NULL
chromatography	NULL
.	NULL

The	NULL
activity	NULL
was	NULL
eluted	NULL
with	NULL
0.5	NULL
M-KCl	NULL
and	NULL
co-migrated	NULL
with	NULL
the	NULL
C1	NULL
complex	NULL
from	NULL
the	NULL
unfractionated	NULL
pool	NULL
1	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

A	NULL
single	NULL
migrating	NULL
activity	NULL
was	NULL
generated	NULL
by	NULL
this	NULL
chromatographic	NULL
step	NULL
;	NULL
however	NULL
,	NULL
recovery	NULL
after	NULL
this	NULL
step	NULL
was	NULL
superior	NULL
to	NULL
that	NULL
obtained	NULL
after	NULL
DEAE	NULL
h.p.l.c	NULL
.	NULL

(	NULL
see	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

One	NULL
possible	NULL
explanation	NULL
for	NULL
this	NULL
enhanced	NULL
yield	NULL
is	NULL
the	NULL
elimination	NULL
of	NULL
an	NULL
inhibitor	NULL
during	NULL
this	NULL
chromatographic	NULL
step	NULL
.	NULL

Similar	NULL
increases	NULL
in	NULL
activity	NULL
were	NULL
recently	NULL
described	NULL
during	NULL
the	NULL
purification	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
from	NULL
bovine	NULL
spleen	NULL
[	NULL
11	NULL
]	NULL
(	NULL
see	NULL
the	NULL
Discussion	NULL
section	NULL
)	NULL
.	NULL

The	NULL
overall	NULL
enrichment	NULL
after	NULL
this	NULL
first	NULL
affinity	NULL
chromatography	NULL
was	NULL
800-fold	NULL
(	NULL
see	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

The	NULL
active	NULL
fractions	NULL
were	NULL
pooled	NULL
and	NULL
refraction-ated	NULL
by	NULL
the	NULL
same	NULL
chromatographic	NULL
procedure	NULL
.	NULL

C1	NULL
activity	NULL
was	NULL
eluted	NULL
in	NULL
two	NULL
fractions	NULL
with	NULL
0.5	NULL
m-KCl	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
second	NULL
step	NULL
resulted	NULL
in	NULL
a	NULL
1000-fold	NULL
overall	NULL
purification	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
but	NULL
recovery	NULL
decreased	NULL
from	NULL
70	NULL
to	NULL
43	NULL
%	NULL
of	NULL
the	NULL
initial	NULL
activity	NULL
.	NULL

C2	NULL
'	NULL
binding	NULL
activity	NULL
from	NULL
pool	NULL
2	NULL
was	NULL
also	NULL
analysed	NULL
by	NULL
affinity	NULL
chromatography	NULL
.	NULL

However	NULL
,	NULL
the	NULL
recovery	NULL
of	NULL
activity	NULL
after	NULL
this	NULL
step	NULL
was	NULL
too	NULL
low	NULL
to	NULL
allow	NULL
further	NULL
analysis	NULL
.	NULL

Molecular-mass	NULL
analysis	NULL
of	NULL
C1	NULL
proteins	NULL
by	NULL
u.v	NULL
.	NULL

cross-linking	NULL
To	NULL
determine	NULL
the	NULL
molecular	NULL
mass	NULL
of	NULL
the	NULL
C1	NULL
proteins	NULL
,	NULL
we	NULL
loaded	NULL
the	NULL
initial	NULL
extract	NULL
directly	NULL
on	NULL
the	NULL
affinity-chromatography	NULL
column	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
mM-EDTA	NULL
.	NULL

The	NULL
C1	NULL
binding	NULL
activity	NULL
was	NULL
eluted	NULL
with	NULL
0.5	NULL
M-KCI	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
single	NULL
fractionation	NULL
step	NULL
permitted	NULL
a	NULL
200-fold	NULL
enrichment	NULL
of	NULL
the	NULL
C1	NULL
activity	NULL
.	NULL

The	NULL
active	NULL
fractions	NULL
were	NULL
then	NULL
u.v.-cross-linked	NULL
with	NULL
*°P-labelled	NULL
BrdUr-substituted	NULL
Tandem	NULL
probe	NULL
as	NULL
described	NULL
in	NULL
the	NULL
Experimental	NULL
section	NULL
.	NULL

Two	NULL
proteins	NULL
of	NULL
47	NULL
kDa	NULL
(	NULL
p47	NULL
)	NULL
and	NULL
Vol	NULL
.	NULL

265	NULL
60	NULL
kDa	NULL
(	NULL
p60	NULL
)	NULL
were	NULL
prominently	NULL
labelled	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
500-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabelled	NULL
competitors	NULL
differentially	NULL
affected	NULL
the	NULL
two	NULL
proteins	NULL
complexed	NULL
with	NULL
the	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

Unlabelled	NULL
Tandem	NULL
probe	NULL
completely	NULL
inhibited	NULL
the	NULL
labelling	NULL
of	NULL
p47	NULL
and	NULL
only	NULL
partially	NULL
inhibited	NULL
p60	NULL
complex	NULL
,	NULL
whereas	NULL
two	NULL
sequence-unrelated	NULL
oligonucleotides	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
CRE	NULL
and	NULL
API	NULL
binding	NULL
sites	NULL
,	NULL
did	NULL
not	NULL
inhibit	NULL
the	NULL
labelling	NULL
of	NULL
p47	NULL
,	NULL
although	NULL
they	NULL
partially	NULL
inhibited	NULL
the	NULL
labelling	NULL
of	NULL
the	NULL
p60	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
.	NULL

The	NULL
IL2Ra	NULL
enhancer	NULL
probe	NULL
partially	NULL
inhibited	NULL
the	NULL
labelling	NULL
of	NULL
both	NULL
p47	NULL
and	NULL
p60	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

When	NULL
u.v	NULL
.	NULL

cross-linking	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
initial	NULL
extract	NULL
,	NULL
many	NULL
proteins	NULL
were	NULL
labelled	NULL
,	NULL
including	NULL
p47	NULL
and	NULL
p60	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
also	NULL
performed	NULL
u.v	NULL
.	NULL

cross-linking	NULL
of	NULL
1000-fold-purified	NULL
C1	NULL
binding	NULL
activity	NULL
by	NULL
both	NULL
the	NULL
DEAE	NULL
h.p.l.c	NULL
.	NULL

and	NULL
the	NULL
two	NULL
affinity-chromatographic	NULL
steps	NULL
(	NULL
see	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

A	NULL
labelled	NULL
protein	NULL
migrated	NULL
with	NULL
an	NULL
apparent	NULL
molecular	NULL
mass	NULL
of	NULL
40	NULL
kDa	NULL
.	NULL

This	NULL
difference	NULL
in	NULL
molecular	NULL
mass	NULL
is	NULL
probably	NULL
due	NULL
to	NULL
partial	NULL
proteolysis	NULL
occurring	NULL
during	NULL
the	NULL
three-step	NULL
purification	NULL
.	NULL

We	NULL
deduce	NULL
from	NULL
the	NULL
u.v.-cross-linking	NULL
data	NULL
that	NULL
the	NULL
protein	NULL
responsible	NULL
for	NULL
C1	NULL
complex-formation	NULL
has	NULL
a	NULL
molecular	NULL
mass	NULL
of	NULL
47	NULL
kDa	NULL
.	NULL

DISCUSSION	NULL
In	NULL
the	NULL
present	NULL
study	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
several	NULL
proteins	NULL
extracted	NULL
from	NULL
mitogen-stimulated	NULL
Jurkat	NULL
cells	NULL
can	NULL
interact	NULL
with	NULL
the	NULL
«	NULL
B	NULL
sites	NULL
that	NULL
are	NULL
contained	NULL
in	NULL
the	NULL
HIV	NULL
enhancer	NULL
domain	NULL
.	NULL

These	NULL
proteins	NULL
differ	NULL
in	NULL
the	NULL
extent	NULL
of	NULL
their	NULL
migration	NULL
during	NULL
non-denaturing	NULL
-	NULL
gel	NULL
electrophoresis	NULL
after	NULL
binding	NULL
with	NULL
oligonucleotides	NULL
.	NULL

They	NULL
also	NULL
differ	NULL
in	NULL
their	NULL
ionic	NULL
requirements	NULL
for	NULL
stable	NULL
interaction	NULL
with	NULL
the	NULL
oligonucleotides	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
Mg**	NULL
on	NULL
C1	NULL
and	NULL
C2	NULL
activities	NULL
is	NULL
summarized	NULL
in	NULL
Table	NULL
2	NULL
.	NULL

The	NULL
552	NULL
6	NULL
2°	NULL
OFT	NULL
Wi	NULL
w2	NULL
C1	NULL
--	NULL
»	NULL
C2	NULL
,	NULL
C2	NULL
``	NULL
-	NULL
>	NULL
»	NULL
Free	NULL
--	NULL
»	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Affinity	NULL
chromatography	NULL
of	NULL
the	NULL
pool-1	NULL
proteins	NULL
M.	NULL
Korner	NULL
and	NULL
others	NULL
1	NULL
2	NULL
The	NULL
Figure	NULL
shows	NULL
the	NULL
gel	NULL
retardation	NULL
of	NULL
**P-labelled	NULL
Mono	NULL
oligonucleotide	NULL
by	NULL
proteins	NULL
from	NULL
fractions	NULL
eluted	NULL
from	NULL
the	NULL
DNA-Sepharose	NULL
column	NULL
.	NULL

The	NULL
retardation	NULL
by	NULL
the	NULL
initial	NULL
extract	NULL
is	NULL
shown	NULL
in	NULL
lane	NULL
I	NULL
.	NULL

The	NULL
pool-1	NULL
lane	NULL
shows	NULL
the	NULL
retardation	NULL
by	NULL
proteins	NULL
before	NULL
affinity-chromatographic	NULL
fractionation	NULL
.	NULL

The	NULL
flow-through	NULL
(	NULL
FT	NULL
)	NULL
and	NULL
column	NULL
washings	NULL
(	NULL
W	NULL
1	NULL
and	NULL
W2	NULL
)	NULL
correspond	NULL
to	NULL
unbound	NULL
material	NULL
.	NULL

Bound	NULL
proteins	NULL
were	NULL
eluted	NULL
in	NULL
ten	NULL
fractions	NULL
(	NULL
lanes	NULL
1-10	NULL
)	NULL
with	NULL
increasing	NULL
concentration	NULL
of	NULL
KCI	NULL
:	NULL
0.2	NULL
m-KCl	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
2	NULL
and	NULL
3	NULL
)	NULL
,	NULL
0.5	NULL
M-KCI	NULL
(	NULL
lanes	NULL
4	NULL
,	NULL
5	NULL
and	NULL
6	NULL
)	NULL
and	NULL
1	NULL
m-KCI	NULL
(	NULL
lanes	NULL
7	NULL
,	NULL
8	NULL
,	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

'Free	NULL
'	NULL
refers	NULL
to	NULL
the	NULL
free	NULL
oligonucleotide	NULL
.	NULL

Table	NULL
1	NULL
.	NULL

Isolation	NULL
of	NULL
p47	NULL
protein	NULL
Specific	NULL
Total	NULL
Protein	NULL
Volume	NULL
activity*	NULL
activity	NULL
Purification	NULL
Recovery	NULL
Step	NULL
(	NULL
mg	NULL
)	NULL
(	NULL
ml	NULL
)	NULL
(	NULL
pe/mg	NULL
)	NULL
(	NULL
P8	NULL
)	NULL
factor	NULL
(	NULL
%	NULL
)	NULL
Extraction	NULL
400	NULL
15	NULL
38	NULL
15200	NULL
1	NULL
100	NULL
DEAE	NULL
h.p.l.c	NULL
.	NULL

11.5	NULL
25	NULL
260	NULL
2990	NULL
6.8	NULL
20	NULL
First	NULL
affinity	NULL
chromatography	NULL
0.328	NULL
6	NULL
32000	NULL
10496	NULL
842	NULL
70	NULL
Second	NULL
affinity	NULL
chromatography	NULL
0.160	NULL
4	NULL
41000	NULL
6560	NULL
1078	NULL
43	NULL
*	NULL
The	NULL
specific	NULL
activity	NULL
was	NULL
defined	NULL
as	NULL
described	NULL
in	NULL
the	NULL
Experimental	NULL
section	NULL
as	NULL
pg	NULL
of	NULL
retarded	NULL
radiolabelled	NULL
probe/mg	NULL
of	NULL
protein	NULL
.	NULL

negative	NULL
effect	NULL
of	NULL
Mg**	NULL
on	NULL
the	NULL
interaction	NULL
of	NULL
the	NULL
inducible	NULL
C1	NULL
DNA-binding	NULL
activity	NULL
suggests	NULL
a	NULL
regulatory	NULL
mechanism	NULL
for	NULL
this	NULL
protein	NULL
,	NULL
because	NULL
Mg**	NULL
has	NULL
been	NULL
also	NULL
shown	NULL
to	NULL
inhibit	NULL
transcription	NULL
assays	NULL
in	NULL
vitro	NULL
with	NULL
the	NULL
SV	NULL
40	NULL
enhancer	NULL
which	NULL
contains	NULL
the	NULL
«	NULL
B	NULL
site	NULL
[	NULL
24	NULL
]	NULL
.	NULL

The	NULL
in-hibitory	NULL
effect	NULL
of	NULL
Mg**	NULL
is	NULL
not	NULL
understood	NULL
,	NULL
but	NULL
it	NULL
could	NULL
cause	NULL
conformational	NULL
changes	NULL
of	NULL
DNA-binding	NULL
proteins	NULL
.	NULL

Using	NULL
two	NULL
different	NULL
chromatographic	NULL
fractionation	NULL
procedures	NULL
we	NULL
partially	NULL
isolated	NULL
an	NULL
inducible	NULL
DNA-binding	NULL
activity	NULL
C1	NULL
and	NULL
identified	NULL
it	NULL
as	NULL
a	NULL
47	NULL
kDa	NULL
protein	NULL
(	NULL
p47	NULL
)	NULL
.	NULL

The	NULL
C2	NULL
'	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
were	NULL
eluted	NULL
from	NULL
DEAE	NULL
at	NULL
lower	NULL
salt	NULL
molarity	NULL
than	NULL
was	NULL
C1	NULL
,	NULL
but	NULL
exhibited	NULL
the	NULL
same	NULL
Mg**-sensitivity	NULL
as	NULL
C1	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

It	NULL
is	NULL
not	NULL
clear	NULL
whether	NULL
the	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
responsible	NULL
for	NULL
C2	NULL
'	NULL
electrophoretic	NULL
mobility	NULL
are	NULL
related	NULL
to	NULL
p47	NULL
.	NULL

C2	NULL
'	NULL
could	NULL
be	NULL
a	NULL
proteolytic	NULL
product	NULL
of	NULL
p47	NULL
or	NULL
it	NULL
may	NULL
be	NULL
a	NULL
modified	NULL
form	NULL
of	NULL
p47	NULL
(	NULL
perhaps	NULL
due	NULL
to	NULL
phosphorylation	NULL
of	NULL
C1	NULL
)	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
active	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
T-cells	NULL
has	NULL
been	NULL
attributed	NULL
to	NULL
dissociation	NULL
from	NULL
a	NULL
cytoplasmic	NULL
inhibitor	NULL
,	NULL
IxB	NULL
[	NULL
28	NULL
]	NULL
,	NULL
which	NULL
allowed	NULL
the	NULL
translocation	NULL
of	NULL
NF-KB	NULL
into	NULL
the	NULL
nucleus	NULL
and	NULL
subsequent	NULL
activation	NULL
of	NULL
transcription	NULL
of	NULL
IL2	NULL
and	NULL
IL2Ra	NULL
genes	NULL
.	NULL

P47	NULL
also	NULL
might	NULL
be	NULL
associated	NULL
with	NULL
an	NULL
inhibitor	NULL
,	NULL
since	NULL
its	NULL
fractionation	NULL
from	NULL
the	NULL
whole-cell	NULL
extract	NULL
by	NULL
affinity	NULL
chromatography	NULL
increased	NULL
binding	NULL
activity	NULL
(	NULL
see	NULL
the	NULL
Results	NULL
section	NULL
,	NULL
in	NULL
particular	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Several	NULL
cellular	NULL
and	NULL
viral	NULL
genes	NULL
,	NULL
including	NULL
the	NULL
«	NULL
light	NULL
chain	NULL
,	NULL
SV	NULL
40	NULL
,	NULL
$	NULL
-microglobulin	NULL
and	NULL
IL2ra	NULL
,	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
contain	NULL
«	NULL
B	NULL
sites	NULL
in	NULL
their	NULL
regulatory	NULL
regions	NULL
[	NULL
10,11,13,20	NULL
]	NULL
.	NULL

In	NULL
HIV-1	NULL
,	NULL
SV	NULL
40	NULL
,	NULL
«	NULL
light	NULL
chain	NULL
and	NULL
#	NULL
-microglobulin	NULL
,	NULL
the	NULL
«	NULL
B	NULL
site	NULL
was	NULL
shown	NULL
to	NULL
regulate	NULL
gene	NULL
1990	NULL
Human	NULL
immunodeficiency	NULL
virus	NULL
enhancer-binding	NULL
proteins	NULL
Lane	NULL
...	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
10-3	NULL
x	NULL
M	NULL
,	NULL
<	NULL
G	NULL
43	NULL
30	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

SDS/polyacrylamide-gel	NULL
electrophoresis	NULL
of	NULL
u.y.-cross-linked	NULL
proteins	NULL
to	NULL
-	NULL
*P-labelled	NULL
BrdUrd-substituted	NULL
Tandem	NULL
oligonucleotide	NULL
Affinity-chromatographically	NULL
purified	NULL
fraction	NULL
(	NULL
0.4	NULL
4g	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
the	NULL
Tandem	NULL
oligonucleotide	NULL
(	NULL
500000	NULL
c.p.m	NULL
.	NULL
)	NULL

alone	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
with	NULL
a	NULL
500-fold	NULL
excess	NULL
of	NULL
competitor	NULL
DNA	NULL
:	NULL
Tandem	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
CRE	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
IL2Ra	NULL
enhancer	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
and	NULL
API	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Table	NULL
2	NULL
.	NULL

Effect	NULL
of	NULL
Mg**	NULL
on	NULL
stability	NULL
of	NULL
protein-Tandem	NULL
oligonucleotide	NULL
complexes	NULL
The	NULL
protein-oligonucleotide	NULL
complexes	NULL
were	NULL
analysed	NULL
by	NULL
the	NULL
gel-retardation	NULL
assay	NULL
.	NULL

The	NULL
MgCl	NULL
,	NULL
concentration	NULL
was	NULL
5	NULL
mm	NULL
.	NULL

PMA	NULL
+	NULL
PHA-	NULL
PMA	NULL
+	NULL
PHA-	NULL
Mg**+-	NULL
Stage	NULL
induced	NULL
non-induced	NULL
-	NULL
dissociated	NULL
Initial	NULL
extract	NULL
Cl	NULL
C2	NULL
C1	NULL
DEAE	NULL
h.p.l.c	NULL
.	NULL

C1	NULL
C2	NULL
Cl	NULL
CZ	NULL
(	NULL
?	NULL
)	NULL

CZ	NULL
transcription	NULL
by	NULL
interacting	NULL
with	NULL
cellular	NULL
proteins	NULL
.	NULL

Some	NULL
«	NULL
kB-site-binding	NULL
proteins	NULL
were	NULL
isolated	NULL
and	NULL
partially	NULL
characterized	NULL
.	NULL

For	NULL
example	NULL
NF-xB	NULL
,	NULL
a	NULL
42-44	NULL
kDa	NULL
protein	NULL
,	NULL
was	NULL
purified	NULL
from	NULL
bovine	NULL
spleen	NULL
cells	NULL
[	NULL
11	NULL
]	NULL
,	NULL
HIVEN	NULL
86A	NULL
,	NULL
a	NULL
86	NULL
kDa	NULL
protein	NULL
,	NULL
was	NULL
found	NULL
in	NULL
mitogen-stimulated	NULL
Jurkat	NULL
cells	NULL
[	NULL
12	NULL
]	NULL
,	NULL
EBP-1	NULL
,	NULL
a	NULL
55-60	NULL
kDa	NULL
protein	NULL
,	NULL
was	NULL
purified	NULL
from	NULL
phorbol-ester-treated	NULL
HeLa	NULL
cells	NULL
[	NULL
14	NULL
]	NULL
,	NULL
and	NULL
H2TFI	NULL
,	NULL
a	NULL
48	NULL
kDa	NULL
protein	NULL
,	NULL
was	NULL
purified	NULL
from	NULL
murine	NULL
thymoma	NULL
cells	NULL
[	NULL
20	NULL
]	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
is	NULL
constitutively	NULL
expressed	NULL
only	NULL
in	NULL
mature	NULL
B-cells	NULL
,	NULL
where	NULL
it	NULL
regulates	NULL
the	NULL
transcription	NULL
of	NULL
«	NULL
light	NULL
chain	NULL
,	NULL
but	NULL
it	NULL
is	NULL
also	NULL
inducible	NULL
in	NULL
T-cells	NULL
,	NULL
where	NULL
it	NULL
might	NULL
regulate	NULL
transcription	NULL
of	NULL
IL2	NULL
and	NULL
IL2Ra	NULL
«	NULL
{	NULL
11,13,26,27	NULL
]	NULL
.	NULL

At	NULL
present	NULL
we	NULL
have	NULL
not	NULL
identified	NULL
with	NULL
certainty	NULL
a	NULL
cellular	NULL
enhancer	NULL
for	NULL
p47	NULL
,	NULL
since	NULL
it	NULL
binds	NULL
IL2Ra	NULL
enhancer	NULL
probe	NULL
with	NULL
much	NULL
lower	NULL
affinity	NULL
than	NULL
HIV-1	NULL
enhancer	NULL
probes	NULL
,	NULL
at	NULL
least	NULL
in	NULL
the	NULL
assays	NULL
in	NULL
vitro	NULL
used	NULL
in	NULL
the	NULL
present	NULL
study	NULL
.	NULL

In	NULL
our	NULL
experiment	NULL
we	NULL
found	NULL
that	NULL
p47	NULL
differs	NULL
in	NULL
size	NULL
Vol	NULL
.	NULL

265	NULL
553	NULL
from	NULL
the	NULL
previously	NULL
described	NULL
Jurkat-cell	NULL
HIV	NULL
enhancer-binding	NULL
protein	NULL
,	NULL
HIVEN	NULL
86A	NULL
[	NULL
12	NULL
]	NULL
,	NULL
as	NULL
well	NULL
as	NULL
from	NULL
the	NULL
HeLa-cell	NULL
HIV	NULL
enhancer-binding	NULL
protein	NULL
,	NULL
EBP-1	NULL
[	NULL
14	NULL
]	NULL
.	NULL

However	NULL
,	NULL
its	NULL
size	NULL
is	NULL
comparable	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
isolated	NULL
either	NULL
from	NULL
bovine	NULL
spleen	NULL
cells	NULL
(	NULL
42-44	NULL
kDa	NULL
)	NULL
[	NULL
11	NULL
]	NULL
or	NULL
a	NULL
human	NULL
B-cell	NULL
line	NULL
(	NULL
51	NULL
kDa	NULL
)	NULL
[	NULL
15	NULL
]	NULL
,	NULL
as	NULL
well	NULL
as	NULL
with	NULL
the	NULL
48	NULL
kDa	NULL
H2TFI	NULL
or	NULL
KBFI	NULL
[	NULL
20	NULL
]	NULL
.	NULL

It	NULL
is	NULL
not	NULL
clear	NULL
whether	NULL
p47	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
H2TFI	NULL
are	NULL
products	NULL
of	NULL
the	NULL
same	NULL
gene	NULL
with	NULL
different	NULL
post-translational	NULL
modifications	NULL
or	NULL
whether	NULL
they	NULL
result	NULL
from	NULL
the	NULL
expression	NULL
of	NULL
different	NULL
genes	NULL
.	NULL

It	NULL
is	NULL
not	NULL
unusual	NULL
for	NULL
several	NULL
different	NULL
proteins	NULL
to	NULL
recognize	NULL
the	NULL
same	NULL
DNA	NULL
sequence	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
mammalian	NULL
transcription	NULL
factor	NULL
c-Jun/AP1	NULL
,	NULL
the	NULL
yeast	NULL
GCN4	NULL
and	NULL
several	NULL
other	NULL
mammalian	NULL
and	NULL
yeast	NULL
proteins	NULL
all	NULL
bind	NULL
to	NULL
the	NULL
same	NULL
consensus	NULL
sequence	NULL
ATGA	NULL
(	NULL
C/G	NULL
)	NULL
TCAT	NULL
(	NULL
see	NULL
[	NULL
25	NULL
]	NULL
for	NULL
review	NULL
)	NULL
.	NULL

H2TFl	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
differ	NULL
by	NULL
their	NULL
«	NULL
B-site-binding	NULL
characteristics	NULL
[	NULL
11,29	NULL
]	NULL
.	NULL

However	NULL
,	NULL
the	NULL
relation	NULL
between	NULL
p47	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
H2TFI	NULL
,	NULL
EBP-1	NULL
and	NULL
HIVEN	NULL
86	NULL
A	NULL
is	NULL
not	NULL
clear	NULL
.	NULL

In	NULL
spite	NULL
of	NULL
several	NULL
described	NULL
differences	NULL
such	NULL
as	NULL
molecular	NULL
mass	NULL
,	NULL
affinities	NULL
for	NULL
«	NULL
B	NULL
site	NULL
and	NULL
modulation	NULL
of	NULL
the	NULL
binding	NULL
to	NULL
«	NULL
B	NULL
site	NULL
by	NULL
nucleotides	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
H2TFI	NULL
and	NULL
p47	NULL
could	NULL
be	NULL
structurally	NULL
related	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
their	NULL
transcriptional	NULL
activity	NULL
could	NULL
be	NULL
due	NULL
to	NULL
different	NULL
post-translational	NULL
modifications	NULL
or	NULL
to	NULL
interaction	NULL
with	NULL
other	NULL
,	NULL
cell	NULL
or	NULL
signal	NULL
,	NULL
specific	NULL
proteins	NULL
.	NULL

We	NULL
thank	NULL
Dr.	NULL
David	NULL
Kelvin	NULL
,	NULL
Dr.	NULL
Douglas	NULL
K.	NULL
Ferris	NULL
and	NULL
Dr.	NULL
Joost	NULL
J.	NULL
Oppenheim	NULL
for	NULL
helpful	NULL
discussion	NULL
and	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
present	NULL
manuscript	NULL
,	NULL
Dr.	NULL
Leo	NULL
Lee	NULL
for	NULL
purification	NULL
of	NULL
the	NULL
synthetic	NULL
oligonucleotides	NULL
and	NULL
Dr.	NULL
Clifford	NULL
E.	NULL
Snyder	NULL
,	NULL
Jr.	NULL
,	NULL
for	NULL
assistance	NULL
during	NULL
the	NULL
h.p.l.c	NULL
.	NULL

fractionation	NULL
procedure	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
Mr.	NULL
Sheldon	NULL
Grove	NULL
and	NULL
Mrs.	NULL
Jami	NULL
Willette-Brown	NULL
for	NULL
expert	NULL
technical	NULL
assistance	NULL
.	NULL

This	NULL
project	NULL
has	NULL
been	NULL
funded	NULL
at	NULL
least	NULL
in	NULL
part	NULL
with	NULL
Federal	NULL
funds	NULL
from	NULL
the	NULL
Department	NULL
of	NULL
Health	NULL
and	NULL
Human	NULL
Services	NULL
under	NULL
contract	NULL
no	NULL
.	NULL

NO1-CO-74102	NULL
with	NULL
Program	NULL
Resources	NULL
,	NULL
Inc	NULL
.	NULL

The	NULL
context	NULL
of	NULL
this	NULL
publication	NULL
does	NULL
not	NULL
necessarily	NULL
reflect	NULL
the	NULL
views	NULL
or	NULL
policies	NULL
of	NULL
the	NULL
Department	NULL
of	NULL
Health	NULL
and	NULL
Human	NULL
Services	NULL
,	NULL
nor	NULL
does	NULL
mention	NULL
of	NULL
trade	NULL
names	NULL
,	NULL
commercial	NULL
products	NULL
or	NULL
organisations	NULL
imply	NULL
endorsement	NULL
by	NULL
the	NULL
U.S.	NULL
Government	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Barre-Sinoussi	NULL
,	NULL
F.	NULL
,	NULL
Chermann	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Rey	NULL
,	NULL
F.	NULL
,	NULL
Nugeyre	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Chamaret	NULL
,	NULL
S.	NULL
,	NULL
Gruest	NULL
,	NULL
J.	NULL
,	NULL
Dauquet	NULL
,	NULL
C.	NULL
,	NULL
Alxer-Blin	NULL
,	NULL
C.	NULL
,	NULL
Vezinet-Brun	NULL
,	NULL
F.	NULL
,	NULL
Rouzioux	NULL
,	NULL
C.	NULL
,	NULL
Rozenbaum	NULL
,	NULL
W.	NULL
&	NULL
Montagnier	NULL
,	NULL
L.	NULL
(	NULL
1983	NULL
)	NULL
Science	NULL
220	NULL
,	NULL
867-888	NULL
2	NULL
.	NULL

Gallo	NULL
,	NULL
R.C	NULL
.	NULL

,	NULL
Salahuddin	NULL
,	NULL
S	NULL
$	NULL
.	NULL

Z.	NULL
,	NULL
Popovic	NULL
,	NULL
M.	NULL
,	NULL
Shearer	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
Keplen	NULL
,	NULL
M.	NULL
,	NULL
Haynes	NULL
,	NULL
B.	NULL
F.	NULL
,	NULL
Palker	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Redfield	NULL
,	NULL
R.	NULL
,	NULL
Oleske	NULL
,	NULL
J.	NULL
,	NULL
Safai	NULL
,	NULL
B.	NULL
,	NULL
White	NULL
,	NULL
G.	NULL
,	NULL
Foster	NULL
,	NULL
P.	NULL
&	NULL
Markhan	NULL
,	NULL
P.	NULL
D.	NULL
(	NULL
1984	NULL
)	NULL
Science	NULL
224	NULL
,	NULL
500-503	NULL
3	NULL
.	NULL

Dalgleish	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
Beverley	NULL
,	NULL
P.C	NULL
.	NULL

L.	NULL
,	NULL
Clapham	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
Crawford	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
Greaves	NULL
,	NULL
M.	NULL
F.	NULL
&	NULL
Weiss	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
312	NULL
,	NULL
763-766	NULL
4	NULL
.	NULL

Klatzman	NULL
,	NULL
D.	NULL
,	NULL
Barre-Sinoussi	NULL
,	NULL
F.	NULL
,	NULL
Nugeyre	NULL
,	NULL
M.T	NULL
.	NULL

,	NULL
Dauguet	NULL
,	NULL
C.	NULL
,	NULL
Vilmer	NULL
,	NULL
E.	NULL
,	NULL
Griscelli	NULL
,	NULL
C.	NULL
,	NULL
Vezinet-Brun	NULL
,	NULL
F.	NULL
,	NULL
Rouzioux	NULL
,	NULL
C.	NULL
,	NULL
Gluckman	NULL
,	NULL
J.	NULL
,	NULL
Chermann	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Montagnier	NULL
,	NULL
L.	NULL
(	NULL
1984	NULL
)	NULL
Science	NULL
225	NULL
,	NULL
59-63	NULL
5	NULL
.	NULL

Levy	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Cheung-Meyer	NULL
,	NULL
C.	NULL
,	NULL
Dina	NULL
,	NULL
D.	NULL
&	NULL
Luciw	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Science	NULL
232	NULL
,	NULL
998-1001	NULL
6	NULL
.	NULL

Garcia	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Wu	NULL
,	NULL
F.	NULL
K.	NULL
,	NULL
Mitsuyasu	NULL
,	NULL
R.	NULL
&	NULL
Gaynor	NULL
,	NULL
R.	NULL
B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

6	NULL
,	NULL
3761-3770	NULL
7	NULL
.	NULL

Rosen	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Sodroski	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Haseltine	NULL
,	NULL
W.	NULL
A	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Cell	NULL
(	NULL
Cambridge	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

41	NULL
,	NULL
813-823	NULL
8	NULL
.	NULL

Muesing	NULL
,	NULL
M.	NULL
,	NULL
Smith	NULL
,	NULL
D.	NULL
H.	NULL
&	NULL
Capon	NULL
,	NULL
D.	NULL
J	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Cell	NULL
(	NULL
Cambridge	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

48	NULL
,	NULL
691-701	NULL
9	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1987	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
326	NULL
,	NULL
711-713	NULL
554	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
(	NULL
Cambridge	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

47	NULL
,	NULL
921-928	NULL
Lenardo	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Kuang	NULL
,	NULL
A.	NULL
,	NULL
Gifford	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
85	NULL
,	NULL
8825-8829	NULL
Franza	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
Josephs	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
Gilman	NULL
,	NULL
M.	NULL
Z.	NULL
,	NULL
Ryan	NULL
,	NULL
W.	NULL
&	NULL
Clarkson	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
330	NULL
,	NULL
391-395	NULL
Bohlein	NULL
,	NULL
E.	NULL
,	NULL
Lowenthal	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Sickevitz	NULL
,	NULL
M.	NULL
,	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Franza	NULL
,	NULL
B.	NULL
R.	NULL
&	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
(	NULL
Cambridge	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

53	NULL
,	NULL
827-836	NULL
Wu	NULL
,	NULL
F.	NULL
K.	NULL
,	NULL
Garcia	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Harrich	NULL
,	NULL
D.	NULL
&	NULL
Gaynor	NULL
,	NULL
R.	NULL
B	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

7	NULL
,	NULL
2117-2129	NULL
Kawakami	NULL
,	NULL
K.	NULL
,	NULL
Schleidereit	NULL
,	NULL
C.	NULL
&	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
85	NULL
,	NULL
4700-4704	NULL
Sorger	NULL
,	NULL
P.	NULL
K.	NULL
&	NULL
Pelham	NULL
,	NULL
H.	NULL
R.	NULL
B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

6	NULL
,	NULL
3035-3041	NULL
Cross	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Feinberg	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
Wolf	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
Holbrook	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Wong-Staal	NULL
,	NULL
F.	NULL
&	NULL
Leonard	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Cell	NULL
(	NULL
Cambridge	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

49	NULL
,	NULL
47-56	NULL
Comb	NULL
,	NULL
M.	NULL
,	NULL
Birnberg	NULL
,	NULL
N.	NULL
C.	NULL
,	NULL
Seasholdz	NULL
,	NULL
A.	NULL
,	NULL
Herbert	NULL
,	NULL
E.	NULL
&	NULL
Goodman	NULL
,	NULL
H.	NULL
M.	NULL
(	NULL
1986	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
323	NULL
,	NULL
353-356	NULL
Received	NULL
25	NULL
July	NULL
1989/accepted	NULL
5	NULL
September	NULL
1989	NULL
19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

M.	NULL
Korner	NULL
and	NULL
others	NULL
Angel	NULL
,	NULL
P.	NULL
,	NULL
Imagawa	NULL
,	NULL
M.	NULL
,	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Stein	NULL
,	NULL
B.	NULL
,	NULL
Imbra	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Ramsorf	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Jonat	NULL
,	NULL
C.	NULL
,	NULL
Herrlich	NULL
,	NULL
P.	NULL
&	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
(	NULL
Cambridge	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

49	NULL
,	NULL
729-739	NULL
Yano	NULL
,	NULL
O.	NULL
,	NULL
Kanellopoulos	NULL
,	NULL
J.	NULL
,	NULL
Kieran	NULL
,	NULL
M.	NULL
,	NULL
Le	NULL
Bail	NULL
,	NULL
O.	NULL
,	NULL
Israel	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Kourilsky	NULL
,	NULL
P.	NULL
(	NULL
1987	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

6	NULL
,	NULL
3317-3324	NULL
Kadona	NULL
,	NULL
J.	NULL
T.	NULL
&	NULL
Tjian	NULL
,	NULL
R.	NULL
(	NULL
1986	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
83	NULL
,	NULL
755-759	NULL
Safer	NULL
,	NULL
B.	NULL
,	NULL
Cohen	NULL
,	NULL
R.	NULL
B.	NULL
,	NULL
Garfinkel	NULL
,	NULL
S.	NULL
&	NULL
Thompson	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cel	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
105-113	NULL
Porzio	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

&	NULL
Pearson	NULL
,	NULL
A.	NULL
M.	NULL
(	NULL
1977	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
490	NULL
,	NULL
27-34	NULL
Wildeman	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
Sassone-Corsi	NULL
,	NULL
P.	NULL
,	NULL
Gunstrom	NULL
,	NULL
T.	NULL
,	NULL
Zenke	NULL
,	NULL
M.	NULL
&	NULL
Chambon	NULL
,	NULL
P.	NULL
(	NULL
1984	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

3	NULL
,	NULL
3129-3133	NULL
Curran	NULL
,	NULL
T.	NULL
&	NULL
Franza	NULL
,	NULL
B.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
(	NULL
Cambridge	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

55	NULL
,	NULL
395-397	NULL
Leung	NULL
,	NULL
K.	NULL
&	NULL
Nabel	NULL
(	NULL
1988	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
33	NULL
,	NULL
776-778	NULL
Ruben	NULL
,	NULL
S.	NULL
,	NULL
Poteat	NULL
,	NULL
H.	NULL
,	NULL
Tan	NULL
,	NULL
T.	NULL
,	NULL
Kawakami	NULL
,	NULL
K.	NULL
,	NULL
Roeder	NULL
,	NULL
R.	NULL
,	NULL
Haseltine	NULL
,	NULL
W.	NULL
&	NULL
Rosen	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Science	NULL
241	NULL
,	NULL
89-92	NULL
Bacuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Science	NULL
242	NULL
,	NULL
540-546	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
&	NULL
Sharp	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
85	NULL
,	NULL
723-727	NULL
1990	NULL

